Acadesine for patients with relapsed/refractory chronic lymphocytic leukemia (CLL): a multicenter phase I/II study-Reference-Cited by-同舟云学术

Acadesine for patients with relapsed/refractory chronic lymphocytic leukemia (CLL): a multicenter phase I/II study

Published:2012-12-11 Issue:3 Volume:71 Page:581-591
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Van Den Neste Eric,Cazin Bruno,Janssens Ann,González-Barca Eva,Terol María José,Levy Vincent,Pérez de Oteyza Jaime,Zachee Pierre,Saunders Andrew,de Frias Mercè,Campàs Clara

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/article/10.1007/s00280-012-2033-5/fulltext.html

Reference22 articles.

1. Dighiero G, Hamblin TJ (2008) Chronic lymphocytic leukaemia. Lancet 371:1017–1029

2. Pleyer L, Egle A, Hartmann TN, Greil R (2009) Molecular and cellular mechanisms of CLL: novel therapeutic approaches. Nat Rev Clin Oncol 6:405–418

3. Butler T, Gribben JG (2010) Biologic and clinical significance of molecular profiling in chronic lymphocytic leukemia. Blood Rev 24:135–141

4. Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, Hensel M, Hopfinger G, Hess G, von Grunhagen U, Bergmann M, Catalano J, Zinzani PL, Caligaris-Cappio F, Seymour JF, Berrebi A, Jager U, Cazin B, Trneny M, Westermann A, Wendtner CM, Eichhorst BF, Staib P, Buhler A, Winkler D, Zenz T, Bottcher S, Ritgen M, Mendila M, Kneba M, Dohner H, Stilgenbauer S, International Group of Investigators, German Chronic Lymphocytic Leukaemia Study Group (2010) Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 376:1164–1174

5. Badoux XC, Keating MJ, Wang X, O’Brien SM, Ferrajoli A, Faderl S, Burger J, Koller C, Lerner S, Kantarjian H, Wierda WG (2011) Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood 117:3016–3024

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. AICAR confers prophylactic cardioprotection in doxorubicin-induced heart failure in rats;Journal of Molecular and Cellular Cardiology;2024-06

2. Pharmacological GLUT3 salvage augments the efficacy of vitamin C-induced TET2 restoration in acute myeloid leukemia;Leukemia;2023-07-01

3. Metabolic reprogramming in cancer: Mechanisms and therapeutics;MedComm;2023-03-27

4. Metabolic Reprogramming and Potential Therapeutic Targets in Lymphoma;International Journal of Molecular Sciences;2023-03-13

5. Cytarabine-induced differentiation of AML cells depends on Chk1 activation and shares the mechanism with inhibitors of DHODH and pyrimidine synthesis;Scientific Reports;2022-07-05